Some of Friday's midday movers:» Read More
Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.
Actavis Plc, Gilead, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.4 percent, while shares of Actavis were up 7.7 percent, Gilead's rose 2.9 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.
Amgen Inc. rose $2.16 or 1.4 percent, to $161.30. Biogen Idec rose $2.95 or 1.0 percent, to $305.37. Celgene Corp. rose $2.53 or 2.4 percent, to $106.89.
Amgen Inc. rose$. 78 or. 5 percent, to $159.92. Biogen Idec rose $3.58 or 1.2 percent, to $306.00. Celgene Corp. rose $1.85 or 1.8 percent, to $106.21.
Amgen Inc. rose $1.46 or. 9 percent, to $159.14. Biogen Idec fell $3.01 or 1.0 percent, to $302.42. Celgene Corp. rose$. 31 or. 3 percent, to $104.36.
Amgen Inc. rose $1.51 or 1.0 percent, to $159.19. Biogen Idec fell $1.03 or. 3 percent, to $304.40. Celgene Corp. rose$. 47 or. 5 percent, to $104.52.
Amgen Inc. rose $1.55 or 1.0 percent, to $159.23. Biogen Idec rose $1.87 or. 6 percent, to $307.30. Celgene Corp. rose $1.12 or 1.1 percent, to $105.17.
Don't worry, be happy. Jim Cramer says these stocks are not affected by the Federal Reserve's announcement to end its bond buying program.
Oct 27- Amgen Inc on Monday reported higher-than-expected third quarter profit and revenue, helped by strong demand for its white blood cell booster, Neulasta, and increased sales of newer drugs, and the company raised its full-year forecast. Amgen shares are up almost 20 percent since the restructuring announcement that involved plant closings and the...
Oct 24- Amgen Inc, one of the world's largest biotechnology companies, will unveil next week its first strategy update since early 2013, but few expect a major shift like the split-up recently proposed by Daniel Loeb's Third Point hedge fund. In a letter to investors on Tuesday, Loeb said Amgen has "all the hallmarks of a hidden value situation" and should divide...
*IBM slumps after quarterly results. NEW YORK, Oct 20- U.S. stocks ended higher on Monday on investor hopes for a strong earnings season, but IBM's disappointing results limited gains. IBM shares slumped 7.1 percent to $169.10, the biggest drag on both the Dow and S&P 500, after third-quarter earnings fell well short of Wall Street expectations.
All too often, investors throw out the proverbial baby with the bathwater. Cramer would hate to see some of them lost down the drain.
An undercurrent that’s been sorely missing from the stock market resurfaced on Wednesday. Cramer thinks you should factor it into your next move.
If you’re looking for stock ideas, Cramer says thanks to good ol’ American ingenuity, this sector is bursting with them.
Check out which companies are making headlines after the bell Tuesday:Bed Bath & Beyond, Viacom, Starbucks & more.
Jim Cramer is always looking near and far for ideas. He just found something big.
Cramer thinks pros are so eager to buy Alibaba they’re willing to throw away perfectly good stocks. That’s silly.
As the Alibaba IPO nears, Cramer expects a slew of stocks to selloff. He's naming names.
Stocks cut losses to close mixed on Thursday as geopolitical tensions lingered ahead of consumer data.
NEW YORK, Sept 11- U.S. stocks were lower on Thursday, with biotechnology shares among the weakest of the day as investors continued to take profits. Celgene Corp was the biggest decliner on the S&P 500, off 3 percent at $91.28, while Vertex Pharmaceuticals was down 2.3 percent at $92.60.